Related Experiment Video
Updated: Apr 22, 2026

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
Published on: June 15, 2019
Vasculitides and the Complement System: a Comprehensive Review
Maria Sole Chimenti1, Eleonora Ballanti2, Paola Triggianese2
1Rheumatology Allergology and Clinical Immunology Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. maria.sole.chimenti@uniroma2.it.
Insights
Systemic vasculitides involve blood vessel inflammation. The complement system (CS) plays a key role in their development and presents a potential therapeutic target for these rare autoimmune diseases.
Area of Science:
- Immunology
- Rheumatology
- Pathogenesis of Autoimmune Diseases
Background:
- Systemic vasculitides are rare autoimmune diseases causing blood vessel inflammation, potentially leading to stenosis or thrombosis.
- The complement system (CS), part of the innate immune system, is implicated in the pathogenesis of various autoimmune conditions, including vasculitides.
- CS activation contributes to inflammation-driven tissue injury and modulates both innate and adaptive immune responses.
Purpose of the Study:
- To review the pathogenetic role of the complement system (CS) in systemic vasculitides.
- To explore the potential therapeutic applications of targeting the CS in these diseases.
Main Methods:
- Literature review of the pathogenetic role of CS in systemic vasculitides.
- Analysis of clinical trial data involving CS modulation.
- Focus on small-to-medium vessel vasculitides.
Main Results:
- The CS is demonstrably involved in the inflammatory damage of systemic vasculitides.
- Evidence supports the efficacy of traditional immunosuppressive therapies.
- CS modulation is an emerging therapeutic strategy, particularly for small-to-medium vessel vasculitides.
Conclusions:
- The complement system is a significant factor in the pathogenesis of systemic vasculitides.
- Targeting the CS offers a promising therapeutic avenue for managing these rare inflammatory conditions.
- Further research into CS modulation is warranted for effective treatment strategies.
Abstract:
Systemic vasculitides are a group of rare diseases characterized by inflammation of the arterial or venous vessel wall, causing stenosis or thrombosis. Clinical symptoms may be limited to skin or to other organs or may include multiple manifestations as systemic conditions. The pathogenesis is related to the presence of leukocytes in the vessels and to the IC deposition, which implies the activation of the complement system (CS) and then the swelling and damage of vessel mural structures. The complement system (CS) is involved in the pathogenesis of several autoimmune diseases, including systemic vasculitides. This enzymatic system is a part of the innate immune system, and its function is linked to the modulation of the adaptive immunity and in bridging innate and adaptive responses. Its activation is also critical for the development of natural antibodies and T cell response and for the regulation of autoreactive B cells. Complement triggering contributes to inflammation-driven tissue injury, which occurs during the ischemia/reperfusion processes, vasculitides, nephritis, arthritis, and many others diseases. In systemic vasculitides, a group of uncommon diseases characterized by blood vessel inflammation, the contribution of CS in the development of inflammatory damage has been demonstrated. Treatment is mainly based on clinical manifestations and severity of organ involvement. Evidences on the efficacy of traditional immunosuppressive therapies have been collected as well as data from clinical trials that involve the modulation of the CS. In particular in small-medium-vessel vasculitides, the CS represents an attractive target. Herein, we reviewed the pathogenetic role of CS in these systemic vasculitides as urticarial vasculitis, ANCA-associated vasculitides, anti-glomerular basement membrane disease, cryoglobulinaemic vasculitides, Henoch-Schönlein purpura/IgA nephropathy, and Kawasaki disease and therefore its potential therapeutic use in this context.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Complement System
Hypersensitivity Reactions: Immune-Complex Reactions
Overview of the Vascular System
Acute Inflammation II: Local and Systemic Effects
Hypersensitivity Reactions: Cytolytic Reactions
Cytotoxic Edema: Pathophysiology